觀點聯合利華

The basic problem with Unilever’s £50bn healthcare bid

Whether or not it buys GSK’s consumer health unit, the company is on the hunt for a big acquisition

Unilever, as we know from Terry Smith, is keen on purpose. And the purpose of its sudden announcement of a strategic rethink and organisational overhaul was very clear: damage limitation.

There’s no use crying over spilled mayonnaise, but the consumer goods group finds itself in a bit of a pickle.

Smith’s broadside last week about purpose-driven condiments and a management team “obsessed with publicly displaying sustainability credentials” highlighted broader investor dissatisfaction with Unilever’s lacklustre performance.

您已閱讀12%(526字),剩餘88%(3793字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×